Please assess the completion status of the following clinical trial:

Trial Title: Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Age over six months.~* Mono-infection with P. falciparum detected by microscopy at a level of 500-150,000/µL asexual forms~* Presence of axillary or tympanic temperature ≥ 37.5 °C or oral or rectal temperature of ≥ 38 °C or history of fever during the past 24 h;~* ability to swallow oral medication;~* ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the patient or from a parent or guardian in the case of children under 18 years of age.~Exclusion criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of the World Health Organization (WHO)~* Mixed or mono-infection with another Plasmodium species detected by microscopy~* Presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm)~* Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);~* Regular medication, which may interfere with antimalarial pharmacokinetics;~* History of hypersensitivity reactions or contraindications to any of the study medications;~* Female over 12 years of age

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- falciparum malaria (Type: None): Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection

Based on this trial design, predict the completion outcome and termination type (if applicable).